Lipid A in Cancer Therapies Preclinical Results

  • Daniele Reisser
  • Jean-François JeanninEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 667)


Studies in animal models showed that the antitumoral effect of LPS and of their biologically active moiety, lipid A, is indirect and relies on the induction of an immune response both innate and specific, leading to cytokine production. They also affect tumor development by inhibiting tumor blood flow and induce necrosis as well as apoptosis of tumor cells. Lipids A have been tested in animals, either alone or as adjuvant in therapeutic vaccines. The efficacy of treatments depends on the type of molecule and on the protocol. In general, increased survival was obtained, accompanied in some cases by tumor regression and cure.


Antitumoral Effect Peritoneal Carcinomatosis Cancer Immunol Tumor Cell Injection Synthetic Lipid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Imoto M, Yoshimura H, Sakaguchi N et al. Total synthesis of Escherichia coli lipid A. Tetrahedron Lett 1985; 26:1545–1548.CrossRefGoogle Scholar
  2. 2.
    Gratia A, Linz R. Le phenomene de Shwartzman dans le sarcome du cobaye. C R Soc Biol 1931; 108:427–428.Google Scholar
  3. 3.
    Shear MJ, Turner FC. Chemical treatment of tumors: isolation of hemorrhagic-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 1943; 4:81–97.Google Scholar
  4. 4.
    Strausser HR, Bober LA. Inhibition of tumor growth and survival of aged mice inoculated with Moloney tumor transplants and treated with endotoxin. Cancer Res 1972; 32:2156–2159.PubMedGoogle Scholar
  5. 5.
    Parr I, Wheeler E, Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer 1973; 27:370–389.PubMedGoogle Scholar
  6. 6.
    Lagadec P, Jeannin JF, Reisser D et al. Treatment with endotoxins of peritoneal carcinomatosis induced by colon tumor cells in the rat. Invasion Metastasis 1987; 7:83–95.PubMedGoogle Scholar
  7. 7.
    Sinkovics JG, Ahearn MJ, Shirato E et al. Viral leukemogenesis in immunologically and hematologically altered mice. J Reticuloendorhel Soc 1970; 8:474–492.Google Scholar
  8. 8.
    Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med 1978; 148:1550–1559.CrossRefPubMedGoogle Scholar
  9. 9.
    Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causesnecrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666–3670.CrossRefPubMedGoogle Scholar
  10. 10.
    Mannel DN, Rosenstreich DL, Mergenhagen SE. Mechanism of lipopolysaccharide-induced tumor necrosis: requirement for lipopolysaccharide-sensitive lymphoreticular cells. Infect Immun 1979; 24:573–576.PubMedGoogle Scholar
  11. 11.
    Inagawa H, Nishizawa T, Takagi K et al. Antitumor mechanism of intradermal administration of lipopolysaccharide. Anticancer Res 1997; 17:1961–1964.PubMedGoogle Scholar
  12. 12.
    Inagawa H, Nishizawa T, Noguchi K et al. Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res 1997; 17:2153–2158.PubMedGoogle Scholar
  13. 13.
    Dighe AS, Richards E, Old LJ et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1:447–456.CrossRefPubMedGoogle Scholar
  14. 14.
    MacPherson GG, North RJ. Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology. Cancer Immunol Immunother 1986; 21:209–216.CrossRefPubMedGoogle Scholar
  15. 15.
    Vukanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499–1504.PubMedGoogle Scholar
  16. 16.
    Blondiau C, Lagadec P, Lejeune P et al. Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species. Immunobiol 1994; 190:243–254.Google Scholar
  17. 17.
    Jibu T, Koike Sando K et al. Antimetastatic activity of lipopolysaccharide against a NK-resistant murine fibrosarcoma. Clin Exp Metastasis 1993; 11:306–312.CrossRefPubMedGoogle Scholar
  18. 18.
    Harmey JH, Bucana CD, Lu W et al. Lipopolysaccharide-induced metastatic growth is associatedwith increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002; 101:415–422.CrossRefPubMedGoogle Scholar
  19. 19.
    Sato K, Yoo YC, Matsuzawa K et al. Tolerance to the anti-metastatic effect of lipopolysaccharide against liver metastasis in mice. Int J Cancer 1996; 66:98–103.CrossRefPubMedGoogle Scholar
  20. 20.
    Ribi E, Amano K, Cantrell J et al. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol Immunother 1982; 12:91–96.CrossRefGoogle Scholar
  21. 21.
    Queshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982; 257: 11808–11815.Google Scholar
  22. 22.
    Ukei S, Iida J, Shiba T et al. Adjuvant and antitumour activities of synthetic lipid A analogues. Vaccine 1986; 4:21–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Shimizu T, Sugiyama K, Iwamoto Y et al. Biological activities of chemically synthesized N acetylated serine-linked lipid A analog in mice. Int J Immunopharmacol 1994; 16:659–665.CrossRefPubMedGoogle Scholar
  24. 24.
    Shimizu T, Iida K, Iwamoto Y et al. Biological activities and antitumor effects of synthetic lipid A analog linked N acetylated serine. Int J Immunopharmacol 1995; 17:425–431.CrossRefPubMedGoogle Scholar
  25. 25.
    Shimizu T, Iwamoto Y, Yanagihara Y et al. Comparison of the biological activity of synthetic N-acylated asparagine or serine linked monosaccharide lipid A analogs. Immunobiology 1996; 196:321–331.PubMedGoogle Scholar
  26. 26.
    Jeannin J-F, Onier N, Lagadec P et al. Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat. Gastroenterology 1991; 101:726–733.PubMedGoogle Scholar
  27. 27.
    Nakatsuka M, Kumazawa Y, Ikeda S et al. Antitumor and antimicrobial activities of lipid A-subunit analogue GLA-27. J Clin Lab Immunol 1988; 26:43–47.PubMedGoogle Scholar
  28. 28.
    Satake K, Yokomatsu H, Hiura A. Effects of a new synthetic lipid A on endogenous tumor necrosis factor production and antitumor activity against human pancreatic cancer cells. Pancreas 1996; 12:260–266.CrossRefPubMedGoogle Scholar
  29. 29.
    Onier N, Lejeune P, Martin M et al. Involvement of T-Iymphocytes in curative effect of a new immunomodulator OM-163 on rat colon cancer metastases. Eur J Cancer 1993; 29A:2003–2009.CrossRefPubMedGoogle Scholar
  30. 30.
    Nakatsuka M, Kumazawa Y, Homma JY et al. Inhibition in mice of experimental metastasis of B16 melanoma by the synthetic lipid A-subunit analogue GL-60. Int J Immunopharmacol 1991; 13:11–19.CrossRefPubMedGoogle Scholar
  31. 31.
    Saiki I, Sato K, Yoo YC. Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). Int J Cancer 1992; 51:641–645.CrossRefPubMedGoogle Scholar
  32. 32.
    Fung PY, Madej M, Koganty RR et al. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990; 50:4308–4314.PubMedGoogle Scholar
  33. 33.
    Ogawa T, Nakazawa M, Masui K. Immunopharmacological activities of the nontoxic monophosphoryl lipid A of Porphyromonas gingivalis. Vaccine 1996; 14:70–76.CrossRefPubMedGoogle Scholar
  34. 34.
    Samuel J, Budzynski WA, Reddish MA et al. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer 1998; 75:295–302.CrossRefPubMedGoogle Scholar
  35. 35.
    Kirman I, Asi Z, Carter J et al. Combined whole tumor cell and monophosphoryllipid A vaccine improved by encapsulation in murine colorectal cancer. Surg Endosc 2002; 16:654–658.CrossRefPubMedGoogle Scholar
  36. 36.
    Kumazawa E, Tohgo A, Soga T et al. Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models. Cancer Immunol Immunother 1992; 35:307–314.CrossRefPubMedGoogle Scholar
  37. 37.
    Sato K, Saiki I, Yoo YC et al. DT-5461, a new synthetic lipid A analogue, inhibits lung and liver metastasis of tumor in mice. Jpn J Cancer Res 1992; 83:1081–1087.PubMedGoogle Scholar
  38. 38.
    Jimbo T, Akimoto T, Tohgo A. Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a and indomethacin in various experimental tumor models of colon 26 carcinoma in mice. Cancer Immunol Immunother 1995; 40:10–16.CrossRefPubMedGoogle Scholar
  39. 39.
    Sato K, Yoo YC, Matsuzawa K et al. Tolerance to the anti-metastatic effect of lipopolysaccharide against liver metastasis in mice. Int J cancer 1996; 66:98–103.CrossRefPubMedGoogle Scholar
  40. 40.
    Akahane K, Someya K, Tsutomi Y et al. Antitumor synthetic lipid A analog DT-5461 upregulates cytokine expression in a murine macrophage cell line through LPS pathway. Cell ImmunoI 1994;155: 42–55.CrossRefGoogle Scholar
  41. 41.
    Akimoto T, Kumazawa E, Jimbo T et al. DT-5461a, an antitumor synthetic lipid a analog, causes selective blood flow reduction in tumor tissue. Anticancer Res 1995; 15:105–107.PubMedGoogle Scholar
  42. 42.
    Kumazawa E, Akimoto T, Kita Y et al. Intratumoral production of tumor necrosis factor augmented by endogenous interferons results in potent antitumor effects of DT-5461, a synthetic lipid A analog. J Imrnunother Emphasis Tumor Immunol 1995; 17:141–150.Google Scholar
  43. 43.
    Sato K, Yoo YC, Mochizuki M et al. Inhibition of tumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461. Jpn J Cancer Res 1995; 86:374–382.PubMedGoogle Scholar
  44. 44.
    Jimbo T, Akimoto T, Tohgo A. Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits. Anticancer Res 1996; 16:359–364.PubMedGoogle Scholar
  45. 45.
    Kobayashi M, Nagayasu H, Hamada J et al. ONO-4007, a new synthetic lipid A derivative, induces differentiation of rat myelomonocytic leukemia cells in vitro and in vivo. Exp Hematol 1994; 22:454–459.PubMedGoogle Scholar
  46. 46.
    Yang D, Satoh M, Ueda H et al. Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 1994; 38:287–293.CrossRefPubMedGoogle Scholar
  47. 47.
    Satoh M, Tsurumaki K, Kagehara H et al. Induction of intrarumoral tumor necrosis factor by a synthetic lipid A analog (ONO-4007) with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity. Cancer Immunol Immunother 2002; 50:653–662.CrossRefPubMedGoogle Scholar
  48. 48.
    Inagawa H, Nishizawa T, Honda T et al. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 1998; 18:3957–3964.PubMedGoogle Scholar
  49. 49.
    Takiguchi K, Nakamoto T, Inagawa H et al. Profile of cytokines produced in tumor tissue after administration of cyclophosphamide in a combination therapy with tumor necrosis factor. ticancer Res 2004; 24: 1823–1828.Google Scholar
  50. 50.
    Morita S, Yamamoto M, Kamigaki T et al. Synthetic lipid A produces antitumor effect in a hamster pancreatic carcinoma model through production of tumor necrosis factor from activated macrophages. Kobe J Med Sci 1996; 42:219–231.PubMedGoogle Scholar
  51. 51.
    Mizushima Y, Sassa K Fujishita T et al. Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at different sites in rats. J Immunother 1999; 22:401–406.CrossRefPubMedGoogle Scholar
  52. 52.
    Kuramitsu Y, Nishibe M, Ohiro Y et al. A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor-alpha in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells. Anticancer Drugs 1997; 8:500–508.CrossRefPubMedGoogle Scholar
  53. 53.
    Kuramitsu Y, Matsushita K, Ohiro Y et al. Therapeutic effect of a new synthetic lipid A analog, ONO-4007, on rat hepatoma KDH-8 depend on tumor necrosis factor-sensitivity of the tumor cells. Anti-cancer Drugs 1997; 8:898–901.CrossRefPubMedGoogle Scholar
  54. 54.
    Matsumoto N, Oida H, Aze Y et al. Intratumoral tumor necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog. Anticancer Res 1998; 18:4283–4289.PubMedGoogle Scholar
  55. 55.
    Matsushita K, Kobayashi M, Totsuka Y et al. ONO-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor-alpha. Anticancer Drugs 1998; 9:273–282.CrossRefPubMedGoogle Scholar
  56. 56.
    Matsushita K, Kuramitsu Y, Ohiro Y et al. ONO-4007, a synthetic lipid A analog, induces Th1-type immune response in tumor eradication and restores nitric oxide production by peritoneal macrophages. Inc J Oncol 2003; 32:489–493.Google Scholar
  57. 57.
    Brandenburg K, Lindner B, Schromm A et al. Physicochemical characteristics of triacyllipid A partial structure OM-174 in relation to biological activity. Eur J Biochem 2000; 267:3370–3377.CrossRefPubMedGoogle Scholar
  58. 58.
    Onier N, Hilpert S, Arnould L et al. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastas 1999; 17:299–306.CrossRefGoogle Scholar
  59. 59.
    Onier N, Hilpert S, Reveneau S et al. Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Int J Cancer 1999; 81:755–760.CrossRefPubMedGoogle Scholar
  60. 60.
    Lejeune P, Lagadec P, Onier N et al. Nitric oxide involvement in tumor-induced immunosuppression. J Immunol 1994; 152:5077–5083.PubMedGoogle Scholar
  61. 61.
    Reisser D, Pance A, Jeannin JE Mechanisms of the antitumoral effect of lipid A. Bioessays 2002; 24:284–289.CrossRefPubMedGoogle Scholar
  62. 62.
    Lagadec P, Raynal S, Lieubeau B et al. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development. Am J Pathol 1999; 154:1867–1876.PubMedGoogle Scholar
  63. 63.
    Lagadec P, Reveneau S, Lejeune P et al. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo. J Pharmacol Exp Ther 1996; 278:926–933.PubMedGoogle Scholar
  64. 64.
    Larmonier CB, Arnould L, Larmonier N et al. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. Int J Mol Med 2004; 13:355–61.PubMedGoogle Scholar
  65. 65.
    D’Agostini C, Pica F, Febbraro G et al. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immununopharmacol 2005; 5:1505–1212.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  1. 1.Tumor Immunology and Immunotherapy Laboratory Inserm U866University of BurgundyDijonFrance

Personalised recommendations